Imprecise risk estimation of chemotherapy-related cardiotoxicity in HER2-positive breast cancer using the recently reported societal risk tools

Breast Cancer Res Treat. 2021 Dec;190(3):355-356. doi: 10.1007/s10549-021-06403-4. Epub 2021 Sep 29.
No abstract available

Publication types

  • Letter

MeSH terms

  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / epidemiology
  • Cardiotoxicity* / etiology
  • Female
  • Humans
  • Receptor, ErbB-2 / genetics
  • Trastuzumab / adverse effects

Substances

  • Receptor, ErbB-2
  • Trastuzumab